Atul Butte - Personalis CoFounder Board

PSNL Stock  USD 3.93  0.20  5.36%   

Insider

Atul Butte is CoFounder Board of Personalis
Address 6600 Dumbarton Circle, Fremont, CA, United States, 94555
Phone650 752 1300
Webhttps://www.personalis.com

Personalis Management Efficiency

The company has return on total asset (ROA) of (0.1878) % which means that it has lost $0.1878 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5752) %, meaning that it created substantial loss on money invested by shareholders. Personalis' management efficiency ratios could be used to measure how well Personalis manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.51. Return On Capital Employed is expected to rise to -0.59 this year. At this time, Personalis' Net Tangible Assets are quite stable compared to the past year. Non Currrent Assets Other is expected to rise to about 2.2 M this year, although the value of Non Current Assets Total will most likely fall to about 48.8 M.
Personalis currently holds 48.96 M in liabilities with Debt to Equity (D/E) ratio of 0.22, which may suggest the company is not taking enough advantage from borrowing. Personalis has a current ratio of 6.13, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Personalis' use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Nicole LambertMyriad Genetics
50
Stephanie CamposIllumina
N/A
Olesya CPANatera Inc
N/A
Pamela WongMyriad Genetics
56
MBA MBASera Prognostics
70
Aaron SatoTwist Bioscience Corp
N/A
Richard AndersonDarioHealth Corp
55
RN RNCastle Biosciences
56
Stephen MSNeuronetics
60
Andrew MacanNeuronetics
51
Susan TousiIllumina
55
Eric EvansNatera Inc
N/A
Jonathan MEngNatera Inc
51
Zhihong ZhangBurning Rock Biotech
48
Kumud KaliaGuardant Health
58
Shaokun ChuaiBurning Rock Biotech
45
Claire SearsNeuronetics
N/A
Dov OppenheimDarioHealth Corp
N/A
Victoria CreamerCharles River Laboratories
54
Carissa RollinsIllumina
54
Michael MBANatera Inc
44
Personalis, Inc. operates as a cancer genomics company worldwide. Personalis, Inc. was incorporated in 2011 and is headquartered in Menlo Park, California. Personalis operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 325 people. Personalis (PSNL) is traded on NASDAQ Exchange in USA. It is located in 6600 Dumbarton Circle, Fremont, CA, United States, 94555 and employs 223 people. Personalis is listed under Life Sciences Tools & Services category by Fama And French industry classification.

Management Performance

Personalis Leadership Team

Elected by the shareholders, the Personalis' board of directors comprises two types of representatives: Personalis inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Personalis. The board's role is to monitor Personalis' management team and ensure that shareholders' interests are well served. Personalis' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Personalis' outside directors are responsible for providing unbiased perspectives on the board's policies.
Christopher Hall, CEO President
Stephen JD, Senior Officer
Christian Haudenschild, Senior Operations
DPHIL FRCP, CoFounder Board
Carol Tillis, VP Admin
MS MD, Executive Officer
MD MS, VP Officer
Aaron Tachibana, CFO COO
John West, CEO, CoFounder
Michael Fitzpatrick, Vice Sales
Atul Butte, CoFounder Board
Deepshikha Bhandari, Quality Regulatory
Stephane Mouradian, Senior Development
Michael Snyder, CoFounder Board

Personalis Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Personalis a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Personalis is a strong investment it is important to analyze Personalis' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Personalis' future performance. For an informed investment choice regarding Personalis Stock, refer to the following important reports:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Personalis. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For more information on how to buy Personalis Stock please use our How to buy in Personalis Stock guide.
You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Personalis. If investors know Personalis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Personalis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.73)
Revenue Per Share
1.637
Quarterly Revenue Growth
0.409
Return On Assets
(0.19)
Return On Equity
(0.58)
The market value of Personalis is measured differently than its book value, which is the value of Personalis that is recorded on the company's balance sheet. Investors also form their own opinion of Personalis' value that differs from its market value or its book value, called intrinsic value, which is Personalis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Personalis' market value can be influenced by many factors that don't directly affect Personalis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Personalis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Personalis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Personalis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.